Assessment of an Automatic Closed-loop Insulin Delivery System

Completed · Not applicable

Conditions studied: Diabetes Mellitus, Type 1

In brief

The overall aim of this research proposal is to determine the safety, feasibility and efficacy of an automatic closed-loop insulin delivery system.

Key facts

Study ID

NCT02366767

Run by

Stanford University

People needed

21

Starts

2014-06-01

Expected to finish

2014-09-01

Last updated by the study team

2017-03-17

Who can join

Age: 14 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of type 1 diabetes
• The diagnosis of type 1 diabetes is based on the investigator's judgment
• C peptide levels and antibody determinations are not required
• Daily insulin therapy for ≥ 12 months
• Insulin pump therapy for ≥ 3 months
• Age 14.0 - 40.0 years
• Subject comprehends written English
• Female subjects who are sexually active must be on acceptable method of contraception e.g. oral contraceptive pill, diaphragm, IUD
• Female subjects past menarche must have a negative urine pregnancy test
• Informed consent form is signed by the subject and/or parent and assent assigned by the subject if under 18 years of age
• For subjects under 18 years, both the subject and parent/guardian understand the study protocol and agree to comply with it. Both parents must sign if possible.

You may not qualify if…

• Subject has a medical disorder that in the judgment of the investigator will affect the wearing of the devices or the completion of any aspect of the protocol
• Diabetic ketoacidosis in the past month
• Hypoglycemic seizure or loss of consciousness or an event requiring glucagon or IV glucose in the past 3 months
• Subject has a respiratory condition such as asthma, treated with systemic or inhaled corticosteroids in the previous 6 months or cystic fibrosis
• Subject has a history of any cardiac or vascular disorder such as myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, arrhythmia or thromboembolic disease
• Subject has a history of liver or kidney disease (other than microalbuminuria)
• Subject has active Graves' disease
• Subjects with inadequately treated thyroid disease or celiac disease
• Subject has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
• Subject has a history of diagnosed medical eating disorder
• Subject has a history of known illicit drug abuse
• Subject has a history of known prescription drug abuse
• Subject has a history of current alcohol abuse
• Subject has a history of visual impairment which would not allow subject to participate
• Subject has an active skin condition that would affect sensor placement
• Subject has adhesive allergies
• Subjects requiring an intermediate or long-acting insulin (such as NPH, detemir or glargine)
• Subjects requiring other anti-diabetic medications other than insulin (oral or injectable)
• Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
• Subject is currently on beta blocker medication
• Subject is currently participating in another investigational study (drug or device)
• Subject is deemed by the investigator to be unwilling or unable to follow the protocol
• Presence of a febrile illness within 24 hours of enrollment

Where it is running

• Camp Conrad-Chinnock — Angelus Oaks, California, United States
• Packard El Camino Hospital — Mountain View, California, United States
• Lucile Packard Children's Hospital — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.